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Abstract
The HSQC NMR spectrum of 15N-cisplatin in cell growth media shows resonances corresponding to the monocarbonato complex,
cis-[Pt(NH3)2(CO3)Cl], 4, and the dicarbonato complex, cis-[Pt(NH3)2(CO3)2]2, 5, in addition to cisplatin itself, cis-[Pt(NH3)2Cl2], 1.
The presence of Jurkat cells reduces the amount of detectable carbonato species by (2.8 ± 0.7) fmol per cell and has little eﬀect on species
1. Jurkat cells made resistant to cisplatin reduce the amount of detectable carbonato species by (7.9 ± 5.6) fmol per cell and also reduce
the amount of 1 by (3.4 ± 0.9) fmol per cell. The amount of detectable carbonato species is also reduced by addition of the drug to medium that has previously been in contact with normal Jurkat cells (cells removed); the reduction is greater when drug is added to medium
previously in contact with resistant Jurkat cells (cells removed). This shows that the platinum species are modiﬁed by a cell-produced
substance that is released to the medium. Since the modiﬁed species have been shown not to enter or bind to cells, and since resistant
cells modify more than non-resistant cells, the modiﬁcation constitutes a new extracellular mechanism for cisplatin resistance which merits further attention.
Ó 2008 Elsevier Inc. All rights reserved.
Keywords: Cisplatin; Resistance; Extracellular; HSQC NMR

1. Introduction
cis-Diamminedichloroplatinum(II), cisplatin (1; Fig. 1),
has been used for decades for the treatment of neck, testicular, and other types of cancer [1–3]. A serious shortcoming with this and other drugs for treating cancer is that
the tumor ultimately becomes resistant to the agent, forcing
the discontinuance of chemotherapy. In the case of cisplatin, resistance mechanisms involving interception of
the drug by cellular thiols, repair of platinated genomic
DNA, rapid eﬄux/reduced uptake, and other processes
are believed to be responsible for the resistance developed
in cisplatin therapy [4–10]. A common feature of all known
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resistance mechanisms is that they are associated with the
cell itself and not the medium outside the cell.
Earlier we used a sensitive technique, heteronuclear single quantum coherence NMR (HSQC NMR) and 15Nlabeled cisplatin to study the eﬀects of Jurkat cells on the
speciation of platinum in the culture medium outside the
cell [11,12]. We found that the platinum species, cis[Pt(NH3)2(CO3)Cl], 4, Fig. 1, which forms in culture medium from the monoaquo/hydroxo species 2/3, is modiﬁed
by Jurkat cells in a manner which depends on the number
of cells present in the medium. In subsequent studies [13]
we showed that each Jurkat cell can modify 2.8 fmol of 4
within 0.6 h and that the modiﬁed platinum does not
bind to the cell. Because there is only a slow decrease
(1.1 ± 0.4 lM h1) in the amount of unmodiﬁed 4
remaining in the medium after 1 h, the cells subsequently lose their ability to modify 4. We suggested that
these results are consistent with a hitherto undocumented
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Fig. 1. Reactions of cisplatin in carbonate media.

extracellular detoxiﬁcation mechanism in which the cells
rapidly modify a portion of 4 in the culture medium.
Subsequent work by us [14] with the anticancer drug carboplatin, [Pt(NH3)2(CBDCA-O,O0 )], where CBDCA is cyclobutane-1,1-dicarboxylate, showed that Jurkat cells can
aﬀect the rate of disappearance of the HSQC NMR peak
for carboplatin in a manner which is dependent on the
number of cells present in the culture medium. Since the
Jurkat cells take up only a small amount of the platinum
present in the medium (<1%), the disappearance of the
HSQC NMR peak of carboplatin cannot be due to absorption of the drug by the cells. The study suggested that the
cells chemically modify carboplatin converting it into to
an NMR-silent species.
Suspecting that these observations may indicate a new
resistance mechanism for the platinum drugs that operates
outside the cell, we made Jurkat cells resistant to cisplatin
and used HSQC NMR to determine if and to what extent
resistant cells can also aﬀect the distribution of platinum
species in the culture medium. In this report we show that
resistant Jurkat cells are much more eﬀective than normal
Jurkat cells in modifying the monocarbonato complex 4
and the dicarbonato complex 5, and that they can also
modify cisplatin, 1. The modiﬁcations take place even
when the cells are removed from the medium, showing that
the platinum-modifying substance is released by the cells to
the medium so that the modiﬁcation takes place outside the
cell. These observations are consistent with a new extracellular resistance mechanism for cisplatin.

2. Materials and methods
2.1. Cisplatin resistant jurkat cells
Resistant Jurkat cells were prepared by exposing nonresistant Jurkat cells to increasing concentrations of
cisplatin (Bedford Laboratories, Bedford, OH), in the concentration range, 1–50 lM, over the course of 5 months.
The cells were maintained in suspension culture under a

fully humidiﬁed atmosphere containing 5% CO2 at 37 °C.
The medium was RPMI-1640 supplemented with 10% (v/
v) FBS, 100 lg/mL streptomycin, 100 IU/mL penicillin,
and 2.0 mM L-glutamine. For concentrations of cisplatin
in the range, 1–10 lM, cells were exposed to drug for
12 h, after which time, the cells were sedimented
(200  g) for 5 min, the drug-containing medium was
removed and the cells were resuspended in fresh medium.
These cells were allowed to recover for 3–4 days before
exposure to a higher concentration of drug. For drug concentrations greater than 10lM, exposure of cells to drug
was 2 h, followed by a 3–4 day recovery period before the
next exposure to drug. Viabilities were assessed by light
microscopy using a hemacytometer under standard trypan
blue staining conditions [15].
2.2. 1H–15N HSQC NMR
The details of the 1H–15N HSQC NMR measurements
involving 15N-labeled were published previously [11].
Brieﬂy described, the NMR experiments were two-dimensional, 1H-15N, with inverse detection and decoupling during acquisition without spinning the sample. Each NMR
experiment involving 65 lM drug in the culture medium
was 62 min (48 scans), giving 103 data points in the proton
dimension and 64 t1 values. The time for the ﬁrst NMR time
point (t = 0) was taken as the NMR data collection time
plus 15 min for temperature equilibration divided by 2
or 0.63 h after the addition of labeled drug to the medium.
The stock solution used in these experiments, which contained 3 mM 15N-labeled cisplatin in 154 mM NaCl, was
allowed to reach equilibrium 24 h before addition of drug
to the medium containing the cells. NMR data for a particular number of cells was collected as a function of time for
the duration of the 10 h experiment, and plots of the concentrations of species present as a function of time constructed. The NMR experiments involving 400 lM drug
were also 10 h in length. In these experiments, spectra were
measured every 16 min for the ﬁrst 4 h and every hour for
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the remaining 6 h. For these experiments 3 mM stock
solutions of labeled drug in either 154 mM (normal saline)
or 105 mM NaCl (chloride ion concentration of RPMI)
were equilibrated for 24 h prior to their use.
The HSQC NMR spectra were collected in a capped
tube at 37 °C using a Bruker DRX500 AVANCE spectrometer (15N; 50.646 MHz) equipped with a 5-mm triple
axis probe. The NMR chemical shifts were referenced
externally to 1 M (15NH4)2SO4 in 95%, 5% H2O/D2O,
which was acidiﬁed to pH 1 by addition of H2SO4.
The 1H chemical shifts were referenced to external
Me3SiCD2CD2CO2Na, 2,2-dimethyl-2-silapentane-5-sulfonate sodium salt, in a 23 mM, pH 7.2, bicarbonate solution. Volume integrations of peaks were obtained using
Bruker software.
The samples for HSQC NMR measurement of the
amounts of platinum species as a function of the number
of resistant Jurkat cells present in the medium were prepared by suspending the desired number of cells in 900 ll
of medium containing 95%/5% H2O/D2O, pH 7.2. Addition of 20 ll of the stock solution of 15N-labeled cisplatin
to the medium gave a ﬁnal concentration of 65 lM total
platinum in the medium in a ﬁnal volume of 920 ll. The
chloride concentration in the ﬁnal solution, controlled by
the RPMI 1640 in the medium, was 105 mM. No NMR
peak for NH3 trans to CO2
3 of 4 was observed for greater
than 5  105 resistant Jurkat cells in the NMR experiment.
Experiments showing that the platinum-modifying substance is released by the cells to the medium were done
as follows: 1.0  107 resistant Jurkat cells were incubated
in 1.0 mL of medium for 1 h in a capped Eppendorf tube
at 37 °C. After 1 h, the cells were sedimented (200  g) for
3 min and the 822 lL of medium containing the cellreleased modifying substance was removed. To the recovered medium were added 50 lL of D2O, and 128 lL of
3.13 mM 15N-cisplatin previously equilibrated in either

154 or 105 mM NaCl to give a ﬁnal concentration of total
platinum of 400 lM in a ﬁnal volume of 1 mL.
3. Results
3.1. Modiﬁcation of species detected by HSQC NMR
To study the eﬀects of resistant Jurkat cells on cisplatin,
the HSQC NMR peak intensities of cisplatin, 1, and its
monocarbonato complex, 4, I1 and I4, respectively,
Fig. 2, were measured as functions of time after the addition of the drug to culture medium containing diﬀerent
numbers of cells. Fitting these plots of intensity vs. time
to exponentials allowed for extrapolation back to t = 0
for each NMR experiment, giving the initial intensity of
the species in the presence of the indicated number of cells.
With no cells present in the culture medium, I1(0) + I4(0)
represents 65 lM drug, giving the conversion factor C
between NMR peak intensity (peak volume) and concentration. As was earlier shown by us [12], the monocarbonato complex 4 has non-equivalent ammonia molecules,
Fig. 1, and at neutral pH, the HSQC NMR peak for the
ammonia molecule trans to Cl of 4 lies under the HSQC
NMR peak for 1. The concentration of 1, for any number
of cells, is then C[I1(0)–I4(0)] and that of 4 is C(2[I4(0)]).
Initial concentrations obtained in this way are plotted
against number of cells (diamonds for 1, squares for 4),
and least-square ﬁt to lines (Fig. 3). With no cells present
in the culture medium the distribution of species in the
65 lM experiments is, [1] = (42.9 ± 2.3) lM and
[4] = (20.2 ± 1.9) lM. The slopes are (3.7 ± 1.0) lM
per million resistant cells for 1 and (8.6 ± 6.1) lM per
million resistant cells for 4. The same analysis earlier
applied to normal Jurkat cells [13] gives slopes of
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Fig. 2. 1H–15N HSQC NMR of 65 lM 15N-cisplatin in the presence of 105
resistant Jurkat cells 1.6 h after the addition of the drug to the culture
medium.

Fig. 3. The concentrations of 1 and 4 immediately after the addition of
65 lM cisplatin to the culture medium (t = 0), as functions of the numbers
of resistant and normal Jurkat cells present in the medium. Black
diamonds and black squares are for cisplatin, 1, and the monocarbonato
complex, 4, respectively, in the presence of resistant Jurkat cells; open
circles are for 4 in the presence of normal cells [13]. The concentrations of
species present at t = 0 were as determined in the Materials and methods.
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(1.0 ± 2.4) lM per million normal cells for 1 and
(2.5 ± 0.8) lM per million cells for 4. The results for 4
with normal Jurkat cells are shown as circles and dashed
line (Fig. 3).
In order to determine the number of moles of each platinum species that is modiﬁed by a single cell, we multiply
the slopes by the reaction volume (920 lL) and divide by
106. We ﬁnd that one resistant cell modiﬁes (3.4 ± 0.9) fmol
of 1 and (7.9 ± 5.6) fmol of 4 in less than 0.6 h (the time
at which we make our ﬁrst NMR measurement). For comparison, a normal Jurkat cell modiﬁes (2.8 ± 0.9) fmol of 4
and only slightly modiﬁes 1, [13].
3.2. Release of the platinum-modifying substance to the
medium
As indicated in the Materials and methods, these experiments were done by placing normal or resistant Jurkat
cells in fresh medium for 1 h, separating the cells from
the medium by centrifugation, adding 15N-cisplatin to the
medium and collecting HSQC NMR data on the medium
containing the drug. In order to decrease the time required
to collect acceptable NMR data, the ﬁnal concentration of
total platinum in these experiments was 400 lM. In addition, stock drug solutions were pre-equilibrated at two different NaCl concentrations, 154 and 105 mM. Typical
NMR results for these experiments are shown in Fig. 4,
with a, b, and c for medium only, medium exposed to normal Jurkat cells, and medium exposed to resistant Jurkat
cells. The true intensities for species 1 and 4 were obtained
as I1–I4 and 2I4, respectively. The intensity of species 5 was
never more than 10% of the intensity of 4. Since 5, a carbonato species like 4, was also attacked by the modifying substance, I5 was added to the intensity of 4 before obtaining
the true intensities.
We expect that intensities for all species decrease with
time because of the slow reaction of these compounds with
substances in the medium [11,13,14], so it is not possible to
obtain the conversion factor between intensities and concentrations. Therefore we have calculated the ratio of the
true intensities for 1 and 4 which is the same as the concentration ratio [1]/[4]. For medium not exposed to cells, the
true intensity for 1 is obtained by subtracting the intensity
for 4 from that of 1 because the second resonance of 4 lies
beneath the resonance of 1. For medium exposed to cells,
the changed pH shifts the second resonance of 4 so that
it is seen directly and subtraction is not necessary.
If the conversion of 1 to 4 is fast relative to the rate of
reaction of these compounds with substances present in
culture media (amino acids, nutrients, etc.), this ratio is
expected to decrease for the ﬁrst few hours (the conversion
of 1 to 4) and then remain constant, assuming that 1 and 4
react at the same rate with substances in culture media. In
Fig. 5 we plot this ratio vs. time for 400 lM cisplatin in (a)
culture medium that has not been exposed to cells, (b) in
medium exposed to normal Jurkat cells, and (c) in medium
exposed to resistant Jurkat cells. The initial decrease in the

Fig. 4. HSQC NMR spectra of 400 lM 15N-cisplatin in culture medium.
(a) Drug in medium not exposed to cells. (b) Drug in medium previously
exposed to 3  106 normal Jurkat cells for 1 h. (c) Drug in medium
previously exposed to 3  106 resistant Jurkat cells for 1 h. Spectra taken
2.6 h after addition of drug to the culture medium. Species are as indicated
in Fig. 1. The stock solution of drug used in these experiments was
equilibrated in 154 mM NaCl.

ratio and its constancy for later times is very clearly shown.
Each set of data was ﬁtted to A + BeCt by minimizing the
mean-square deviation, as shown. The value of the ratio at
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medium previously exposed to normal cells, 22.2 ± 1.0
and for medium previously exposed to resistant cells
27.8 ± 1.3. Since the ratio [1]/[4] is greatest for resistant
cells, they are more eﬀective than normal cells in modifying
4 in the culture medium. While this same conclusion was
reached in NMR experiments having the cells in contact
with the drug (Fig. 3), Fig. 5 shows that the modifying substance is released by the cells and that the modiﬁcation
takes place in the medium.

Ratio of intensities

16

12

8

4

4. Discussion
0
0

1

2

3

4

5

4

5

4

5

Time in hours

Ratio of intensities

25

20

15

10

5

0
0

1

2

3

Time in hours

Ratio of intensities

30

20

10

0
0

1

2

3

Time in hours
Fig. 5. Ratio of concentration of species 1 to concentration of species 4 in
culture media from HSQC NMR, as function of time. Total concentration
of drug, 400 lM, from a stock solution pre-equilibrated in 105 mM NaCl.
(a) 15N-cisplatin in culture medium not exposed to cells, (b) 15N-cisplatin
in medium previously exposed to normal Jurkat cells, (c) 15N-cisplatin in
medium previously exposed to resistant Jurkat cells. Each data set is ﬁtted
to A + BeCt by least-squares.

t = 0 (just after the reaction of cisplatin with substances in
the medium) is A + B. For culture medium which has not
been exposed to cells, the value is 12.1 ± 0.3, for culture

Fig. 3 shows the concentrations of cisplatin, 1, and its
monocarbonato complex, 4, 0.6 h after adding 65 lM cisplatin to suspensions containing culture medium and the
indicated numbers of normal or resistant cells. As is shown
in the plot, resistant Jurkat cells are much more eﬀective in
modifying 4 in the culture medium than are normal Jurkat
cells. The linear ﬁts shown have slopes of 3.7 and
8.6 lM per million resistant cells for species 1 and 4;
for normal cells, the slopes are 0 (not shown – the actual
value is +1.0 ± 2.4 lM per million cells [13]) and 2.4 lM
per million cells for species 1 and 4. This means that a single normal cell modiﬁes 2.8 fmol of 4, and a single resistant
Jurkat cell modiﬁes 3.4 fmol of 1 and 7.9 fmol of 4. Cisplatin, 1, is more resistant to attack by the modifying substance in the medium than is 4, whether the substance is
produced by normal or resistant cells.
The conclusion that resistant cells can modify more 4
than normal cells is conﬁrmed in the 400 lM experiments
shown in Figs. 4 and 5. However, since the cells were no
longer present when the NMR data were collected, it is
clear that the platinum-modifying substance is released
by the cells to the medium. It is also clear that this modifying reaction is rapid, occurring prior to the ﬁrst NMR measurement, less than 16 min. Because more 4 than 1 is
modiﬁed by the cell-released substance, the platinum species re-equilibrate at early times, i.e., 1 converts to 4, producing the exponential decay observed in Fig. 5. At later
times, after the platinum species reach equilibrium with
each other, the absolute intensities of both decrease slowly
with time [11]. Since their ratio remains constant, they
appear to react at equal rates with substances in the
medium.
Although both the nature of the substance released by
cells and the products formed are unknown, some explanations for the loss of the HSQC NMR signals can be ruled
out. For example, while the platinum drugs readily react
with thiols by ligand displacement, the initial products of
these reactions, which have NH3 trans to S are easily
detected by HSQC NMR [13,16,17]. The fact that no
HSQC NMR active product peaks are observed at
40 ppm (N), strongly suggests that attack by thiols,
e.g. GSH, is not responsible for the modiﬁcation of 1 and
4 in these studies. Another possibility for the loss of peak
intensity is that the platinum compounds are binding to a
macromolecule, which broadens NMR lines making
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signals undetectable. However, earlier studies by Sadler
and coworkers showed that HSQC NMR peaks for 15N
cisplatin are easily observed when the drug is bound to
the 66 kD protein, human serum albumin [18]. It seems
unlikely that the cell releases a high molecular weight protein for the modiﬁcation of these platinum compounds.
Furthermore, the amount of platinum compounds taken
up by, or bound to, cells [13] is much less than the decrease
in peak intensity seen in the HSQC NMR.
Most important, the modiﬁcation of species 1 and 4
takes place in the absence of cells, so is an extracellular process. Since previous experiments [13] have shown that the
modiﬁed species, which are HSQC NMR-silent, do not
enter cells, this modiﬁcation is a mechanism for drug resistance. Despite the fact that the molecular mechanisms of
resistance to the platinum drugs have been studied for decades, inquiry in this area has largely focused in what happens after the drug enters the cell. However, recent studies
suggest that tumors can recognize and reorganize their
microenvironment to maximize their survival in the presence of anticancer drugs [18,19]. This ability, which has
an important impact on the success of chemotherapy,
could be the basis for an extracellular resistance mechanism
that modiﬁes toxins before they have the chance to penetrate the membrane and enter the cell.
In this report we use a sensitive NMR technique, HSQC
NMR, to show that a substance released by Jurkat cells can
modify cisplatin and its mono- and dicarbonato complexes
in the culture medium. Since resistant Jurkat cells are able
to modify more of the platinum compounds than normal
cells, this appears to be an undiscovered resistance mechanism for cisplatin that operates outside the cell. In view of
the fact that acquired resistance is one of the major limitations in platinum chemotherapy; this observation can have
important consequences for the design of new platinum
drugs for treating cancer. We hope that this report will
stimulate interest in the role of carbonate in the molecular
mechanism of action of the platinum drugs.
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